Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy

Antibody therapy is a treatment option for several diseases, including multiple myeloma. The logic behind it is relatively simple: A target molecule is selected because of its expression on tumor cells, and the antibody delivers cytotoxic effects. Therapeutic results in multiple myeloma indicate tha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2019-05, Vol.25 (10), p.2946-2948
Hauptverfasser:	Malavasi, Fabio, Faini, Angelo Corso
Format:	Artikel
Sprache:	eng
Schlagworte:	ADP-ribosyl Cyclase 1 - immunology Antibodies, Monoclonal Humans Immunologic Factors Immunotherapy Multiple Myeloma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Antibody therapy is a treatment option for several diseases, including multiple myeloma. The logic behind it is relatively simple: A target molecule is selected because of its expression on tumor cells, and the antibody delivers cytotoxic effects. Therapeutic results in multiple myeloma indicate that the anti-CD38 antibodies may have relevant immunotherapeutic properties. .
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-19-0260